Voyager Therapeutics is developing VY1706, a gene therapy designed to reduce tau protein activity in the brain — a key driver of Alzheimer's progression. The breakthrough isn't just the target; it's the delivery. Rather than invasive brain injections, VY1706 is administered through a standard IV infusion, using engineered viral capsids that cross the blood-brain barrier naturally. A three-month safety study in non-human primates showed promising pharmacology and no major safety flags. Voyager plans to move into human clinical trials in the second half of 2026. For longevity-focused readers, this represents a shift from symptom management toward rewriting disease biology at the genetic level — potentially making Alzheimer's treatment more accessible and scalable if the approach holds up in humans.
